Retatrutide vs Foundayo (orforglipron) — TRIUMPH-1 vs ATTAIN-1 cross-trial evidence

This cross-trial comparison lives in Weight Loss Rankings' living editorial database — 300+ research articles and 200+ clinically-verified GLP-1 telehealth providers, sourced only from primary FDA labels, ClinicalTrials.gov registrations, and peer-reviewed PubMed literature.

The honest answer: Foundayo (orforglipron) is FDA-approved for chronic weight management (April 1, 2026 — the first oral GLP-1 receptor agonist ever approved for obesity) and retatrutide is still investigational. Both are Eli Lilly molecules but use different mechanisms: retatrutide is an injectable triple GIP/GLP-1/glucagon agonist; Foundayo is a daily small-molecule GLP-1 pill. Cross-trial, retatrutide produced roughly 2.5× the mean TBWL of Foundayo (−28.3% vs ~−11%).

At a glance

• Approval: Foundayo is FDA-approved (April 1, 2026); retatrutide is investigational (Phase 3 TRIUMPH program ongoing).^[2][3]
• Route: Foundayo is a once-daily oral tablet; retatrutide is a once-weekly subcutaneous injection.^[9][3]
• Mechanism: Foundayo activates GLP-1 only (single receptor); retatrutide activates GIP + GLP-1 + glucagon receptors (triple agonist).^[1][2]
• Weight loss (cross-trial): TRIUMPH-1 retatrutide 12 mg ~−28.3% mean TBWL at 80 weeks vs ATTAIN-1 Foundayo 17.2 mg ~−11% mean TBWL at 72 weeks — roughly a 2.5× multiplier in favor of retatrutide.^[2][3]
• GI burden: Both classes have substantial GI adverse events; orforglipron's oral small-molecule kinetics produce a slightly different titration curve than injectable peptides, but discontinuation rates are broadly comparable to other monoagonist GLP-1s.^[2]
• Manufacturer: Both are Eli Lilly. This is a within-portfolio decision, not a brand-vs-brand-competitor comparison.
• Cross-trial caveat: No head-to-head trial exists. TRIUMPH-1 and ATTAIN-1 differ in duration, baseline population, and dose ladders. The 2.5× multiplier is the best available approximation, not a randomized comparison.

Approval status — Foundayo FDA-approved April 2026, retatrutide investigational

Foundayo (orforglipron) became the first oral GLP-1 receptor agonist FDA-approved for chronic weight management on April 1, 2026. The label covers adults with obesity (BMI ≥ 30) and adults with overweight (BMI ≥ 27) plus at least one weight-related comorbidity, with a four-step dose ladder (3 / 6 / 12 / 17.2 mg once daily) and 30-day minimum intervals between increases. Section 14 of the prescribing information reports the 17.2 mg labeled-dose efficacy in the ATTAIN-1 population without type 2 diabetes.^[9]

Retatrutide is not FDA-approved. The TRIUMPH-1 pivotal Phase 3 trial (NCT05929066) reported in May 2026 via Eli Lilly investor release — roughly −28.3% mean TBWL at the 12 mg dose over 80 weeks — but the Biologics License Application has not yet been filed. The most-cited expected approval window is 2027, with earliest commercial availability potentially slipping into 2028 depending on FDA review and post-marketing-commitment terms.^[3][8]

Practical implication for a 2026 patient: only Foundayo can be prescribed and filled today. Retatrutide remains a clinical-trial-only molecule. Any "compounded retatrutide" marketed in 2026 is not produced under the FDCA 503A framework — retatrutide is not on the FDA bulk substance list, has no USP monograph, and is not a discontinued FDA-approved drug. See our retatrutide vs tirzepatide head-to-head for the full regulatory walk-through.

Mechanism — injectable triple agonist vs oral small-molecule GLP-1 RA

Foundayo is a small-molecule non-peptide compound that binds the GLP-1 receptor only. Because it is a small molecule rather than a peptide, it can be formulated as an oral tablet absorbed through the GI tract without the strict empty-stomach plus 4-ounce water requirements of Rybelsus (oral semaglutide). Foundayo can be taken at any time of day, with or without food. It activates a single receptor — the same GLP-1R target that Wegovy, Saxenda, and Rybelsus hit.^[2][9]

Retatrutide is a synthetic peptide that activates three receptors simultaneously: GIP, GLP-1, and glucagon. The glucagon-receptor component is what makes retatrutide categorically different from every FDA-approved obesity drug. Glucagon receptor activation increases hepatic energy expenditure, promotes lipolysis, and reduces hepatic steatosis — mechanisms that single-receptor GLP-1 agonists like Foundayo cannot access.^[1][7]

The mechanism asymmetry is also the magnitude asymmetry. Triple receptor activation drives larger weight loss but also amplifies the adverse-event signal — particularly a unique dysesthesia/paresthesia signal observed in TRIUMPH-1 that does not appear in oral GLP-1 monoagonist trials.^[1]

Weight loss cross-trial — ~2.5× multiplier in favor of retatrutide

The cleanest mean-effect numbers from each pivotal Phase 3 are:

• Retatrutide 12 mg / 80 weeks (TRIUMPH-1): roughly −28.3% mean total body weight loss on the treatment-regimen estimand; the BMI ≥ 35 extension cohort reached approximately −30.3% at 104 weeks.^[3][8]
• Foundayo 17.2 mg / 72 weeks (ATTAIN-1): approximately −11% mean TBWL at the FDA-approved labeled max dose in adults with obesity without type 2 diabetes (Section 14 of the US Prescribing Information).^[2][9]

Dividing the two gives a roughly 2.5× cross-trial multiplier in favor of retatrutide. As an absolute pp number, the gap is about 17 percentage points of TBWL at maximum tested dose. The ≥30% TBWL response rate also separates sharply: roughly 45% of TRIUMPH-1 retatrutide 12 mg participants reached that threshold, while ATTAIN-1 Foundayo 17.2 mg places far fewer patients in the ≥30% bucket.^[3][2]

Cross-trial caveat. TRIUMPH-1 and ATTAIN-1 are not a randomized head-to-head. They differ in duration (80 vs 72 weeks), dose ladder, baseline BMI distribution, and the secular context of trial conduct. They are also different molecules — peptide vs small molecule — administered by different routes. The 2.5× number is the best approximation from publicly reported data, not a head-to-head finding. A prescriber making an individual decision should treat this magnitude gap as directional rather than precise.

Route + frequency — weekly injection vs daily oral pill

Foundayo is a once-daily tablet. It is a small molecule, not a peptide — so it survives gastric digestion and is absorbed via the GI tract without the strict empty-stomach window that Rybelsus requires. Patients take one pill at the same time each day, with or without food.^[9]

Retatrutide in the TRIUMPH program is a once-weekly subcutaneous injection administered into the abdomen, thigh, or upper arm via a prefilled pen device, with a multi-month dose-escalation ladder. Refrigerated storage is required for the unopened product (consistent with the rest of the GLP-1 injectable class).^[1]

For needle-averse patients, this is the decisive practical difference. Roughly 30-40% of adults report needle anxiety sufficient to delay or refuse injectable medication. Foundayo is the first FDA-approved oral path to clinically meaningful weight loss in this population. The trade-off is that mean TBWL is roughly 2.5× lower than retatrutide's pivotal magnitude — patients who would never start an injectable at all may still achieve clinically meaningful weight loss on a daily pill they will actually take.

Side-effect profile cross-trial

Both classes have substantial gastrointestinal AEs. The exact rates and kinetics differ:

• Foundayo 17.2 mg / ATTAIN-1: nausea, diarrhea, constipation, vomiting, and dyspepsia dominate. Treatment-emergent AE discontinuations ran roughly 5.3-10.3% in ATTAIN-1 at the labeled-max dose — broadly comparable to STEP-1 Wegovy (~7%) and SURMOUNT-1 Zepbound (4.3-7.1%). GI events were mostly mild to moderate and concentrated during the titration window. See our Foundayo side effects comprehensive review for the full AE table.^[2]
• Retatrutide 12 mg / TRIUMPH-1: nausea ran roughly 42.4% (vs ~14.8% placebo), diarrhea ~27%, vomiting ~16%, constipation ~14%. AE discontinuation ran ~11.3% on the 12 mg dose. A categorically different finding is dysesthesia / paresthesia (altered or unpleasant skin sensation) at roughly 12.5% — a signal not seen with oral GLP-1 monoagonists.^[1][3]

Oral small-molecule GLP-1 kinetics also differ from injectable peptides — Foundayo's daily dosing produces a more consistent receptor-occupancy profile than weekly-pulse injectable peptides, and some prescribers report that titration nausea is qualitatively different (smaller peaks, longer baseline). This has not been quantified in a head-to-head trial; it is a clinical observation reported across the ATTAIN program.

Both labels carry the standard GLP-1 class warnings: boxed warning for thyroid C-cell tumor risk, pancreatitis, gallbladder disease, acute kidney injury, hypersensitivity, and pregnancy contraindications. Foundayo also carries a specific 9 mg dose cap with strong CYP3A4 inhibitors (Section 7 of the US Prescribing Information) — a small molecule's metabolic profile creates drug-drug interactions that the peptide GLP-1 class does not have.^[9]

When the oral pill makes more sense

Foundayo is the right choice when:

• Needle aversion is the gating barrier. A patient who would refuse an injectable will achieve more weight loss on a daily pill than on no medication.
• BMI 27-35 seeking 8-12% TBWL. The ATTAIN-1 mean is well-matched to this magnitude target; the cost of retatrutide's stronger effect is not warranted when the goal sits inside Foundayo's delivered range.
• Travel-heavy lifestyle with refrigeration constraints. Foundayo is room-temperature stable and a single pill — substantially simpler than weekly injectable logistics.
• You can fill the prescription this month. Retatrutide is not legally available outside of TRIUMPH-3 / TRIUMPH-4 / TRIUMPH-5 enrollment. For the 2026 patient, Foundayo is the only oral option and one of only four FDA-approved monoagonist GLP-1 paths (alongside Wegovy, Saxenda, and Rybelsus).

Honest tradeoff: lower mean efficacy. A 17 percentage-point gap in mean TBWL is meaningful for high-BMI patients targeting bariatric-range outcomes. For those patients, the right comparison is Foundayo vs an injectable like Zepbound or Wegovy today — and retatrutide later, if FDA approval lands.

When the triple-class injectable makes more sense

Retatrutide will be the right choice (post-approval) when:

• BMI ≥ 40 and the target is bariatric-range outcomes. The ≥30% TBWL response rate on retatrutide 12 mg approaches sleeve gastrectomy magnitudes — territory no oral GLP-1 monoagonist reaches.
• Failed an oral GLP-1 RA on efficacy. A patient who completed the ATTAIN-style titration and reached a plateau at 8-10% TBWL while still needing 20-25% to clear comorbidity thresholds is the canonical retatrutide candidate.
• Comfortable with weekly injection logistics. Patients already injecting Zepbound or Wegovy successfully have functionally cleared this barrier.
• No active dysesthesia history or peripheral neuropathy. The ~12.5% retatrutide paresthesia signal is the cleanest specific contraindication in the comparative dataset.

The honest framing for 2026: retatrutide is not yet a choice. For high-BMI patients today, the practical comparison is Foundayo vs Zepbound, with retatrutide as a future option once approval lands.

Cost + availability

Foundayo is available through standard retail pharmacies, LillyDirect, and the Foundayo Self Pay Pharmacy portal. Eli Lilly launched a direct-pay self-pay pricing structure analogous to the Zepbound NovoCare-equivalent vial program, but because Foundayo is a tablet, the self-pay logistics are simpler — no cold chain, no pen device manufacturing constraints, no dose-specific supply allocations.^[10]

Retatrutide is not commercially available. There is no list price, no PBM formulary placement, no insurance prior authorization pathway, and no self-pay portal. The only legal access route in 2026 is enrollment in an active TRIUMPH trial. For the pricing mechanisms that will eventually apply once retatrutide is approved, see our retatrutide cost mechanism review.

Eli Lilly's pipeline rationale for both molecules

Both retatrutide and Foundayo are Eli Lilly assets — this is a within-portfolio decision, not a brand-vs-competitor framing. Lilly's strategy spans three monoagonist GLP-1 paths (Trulicity injectable, Foundayo oral, Mounjaro/Zepbound dual agonist) plus the retatrutide triple-class program. Each molecule targets a distinct patient archetype:

• Foundayo: the oral path. Captures the needle-averse market that injectable GLP-1s never reached and serves patients with weight loss targets in the 8-12% range.
• Zepbound (tirzepatide): the dual-agonist injectable. Today's gold standard for 20%-range TBWL — broadly available, established prior authorization pathways, established post-marketing safety record.
• Retatrutide: the triple-class injectable. Lilly's candidate for the bariatric-range pharmacotherapy tier — once approved, it will likely sit above Zepbound on formularies for high-BMI patients targeting ≥25% TBWL.

From a patient's standpoint, all three Lilly options offer LillyDirect logistics and the same underlying manufacturer track record. A patient who switches from Foundayo to Zepbound to retatrutide over time will likely do so under the same prescribing infrastructure — which makes these comparisons less about brand loyalty and more about clinical fit.

Practical takeaway

For most patients in 2026, the decision reduces to two clinical questions:

• How much weight do you need to lose? If the target is 8-12% TBWL, Foundayo's oral path is fitted to the magnitude and avoids weekly injection. If the target is 20%+ TBWL (clearing comorbidity thresholds, approaching bariatric magnitudes), Foundayo is unlikely to deliver — discuss Zepbound today and retatrutide in 2027+.
• Can you live with a weekly injection? Patients who would not start an injectable at all should start Foundayo and reassess. Patients comfortable with weekly injection have access to a meaningfully larger efficacy ceiling today via Zepbound and (post-approval) via retatrutide.

Every individual prescribing decision should be made with a licensed clinician who can review the full FDA prescribing information for Foundayo, the patient's comorbidities, drug-drug interactions (particularly CYP3A4 inhibitors for Foundayo), and prior tolerability with the GLP-1 class. Retatrutide remains investigational and cannot be prescribed outside of TRIUMPH-program enrollment in 2026.

Related research

• Sister cross-trial: Retatrutide vs tirzepatide — TRIUMPH-1 vs SURMOUNT-1 head-to-head evidence — the comparison against today's injectable gold standard, also a within-Lilly portfolio comparison.
• Foundayo's injectable comparator: Foundayo vs Wegovy — head-to-head evidence comparison — the oral-vs-injectable monoagonist comparison most patients face when choosing Foundayo.
• Foundayo safety detail: Foundayo (orforglipron) side effects — comprehensive evidence review — the full ATTAIN-1, ATTAIN-2, ATTAIN-MAINTAIN AE table and CYP3A4 dose-cap analysis.
• Triple-agonist mechanism: Retatrutide as a triple GIP/GLP-1/glucagon agonist — evidence review — why a third receptor changes the magnitude ceiling.
• TRIUMPH-1 deep dive: Retatrutide before and after — what TRIUMPH-1 actually showed — magnitude, dose-response, and how real-world results typically run 60-80% of pivotal-trial TBWL.